10.81
-0.73%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hubei Biocause Heilen Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 301211.SZ. It has been listed since 22 December 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥453.3m and net income of CN¥34.9m. At that date it held total assets of CN¥2.40bn and shareholders' equity of CN¥2.27bn.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the production and sale of tablets, hard capsules, granules, active pharmaceutical ingredients, and large-volume injections. The company is headquartered in Jingmen, Hubei. The company went IPO on 2021-12-22. The firm's products can be divided into non-steroidal anti-inflammatory, cardiovascular and anti-tumor. The API products include Ibuprofen, D-Ibuprofen, Torasemide, Milrinone, Abiraterone Acetate, Granisetron Hydrochloride, Fludarabine Phosphate and others. The preparation products include Ibuprofen Granules, Ibuprofen Tablets, Ibuprofen Pseudoephedrine Tablets, Oxaprozin Enteric Coated Tablets, Oxaprozin Enteric Coated Capsules, Torasemide Tablets and others. The firm's products are exported to India, the United States, the European Union, South Korea and other countries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Dec 2021
- Employees
- 953
- Website
- biocause.com ↗
Leadership
Pay as last reported
- Mr. Zhigang ChengChairman of the Board, since 2020CN¥657,900
- Mr. Tinghao YiChief Financial OfficerCN¥388,800
- Mr. Qun LiangGeneral ManagerCN¥394,800
- Mr. Jian GaoDeputy General Manager, Secretary of the BoardCN¥371,600
- Ms. Chunli YangExecutive Deputy General Manager, Director, since 2020CN¥316,200
- Mr. Zhenghua HuangDeputy General ManagerCN¥338,300
- Ms. Kuili ZhangDeputy General ManagerCN¥789,800
- Mr. Weihua ZhuDeputy General ManagerCN¥337,600
- Mr. Xueqiang HuangDirector
- Mr. Xiaobing ZhuDirector
- Mr. Renhui FuIndependent DirectorCN¥84,000
- Mr. Guangya XiangIndependent DirectorCN¥84,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Produces Ibuprofen and other API products for global markets
- Exports pharmaceuticals to India, US, EU, and South Korea
- Has a diverse product portfolio including cardiovascular and anti-tumor drugs
Weaknesses
- Limited to 953 employees for production and sales
- IPO in 2021 may indicate early-stage financial constraints
- Relies on specific API ingredients like Ibuprofen and Torasemide
Opportunities
- Expanding into new markets beyond current export destinations
- Growing demand for cardiovascular and anti-tumor drugs globally
- Increasing focus on API production for international pharmaceutical companies
Threats
- Competition from established pharmaceutical firms in global markets
- Regulatory changes affecting API exports to EU and US
- Economic downturns impacting pharmaceutical exports to key regions
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.